Pricing

Micromet Inc (MITI)

followers ·
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
2110 RUTHERFORD CARLSBAD, CA 92008

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Stock Split History
DateRatio
2006-05-09 1:4
Micromet, Inc., a biopharmaceutical company, develops antibody-based products for cancer, inflammatory, and autoimmune diseases. Its products under clinical trials include MT103, a Phase I clinical trial product candidate for the treatment of patients with non-Hodgkins lymphoma; and Adecatumumab, a recombinant human monoclonal antibody that is under clinical Phase IIa status for metastatic breast cancer and other adenocarcinoma indications, and is being evaluated in clinical Phase Ib trials for treatment of metastatic breast cancer in combination with docetaxel. The company's preclinical development products include MT203 and MT204 human antibodies to treat various acute and chronic inflammatory diseases, including rheumatoid arthritis, asthma, psoriasis, and multiple sclerosis; EphA2, a cell surface membrane-associated receptor tyrosine kinase for the treatment of cancer; CEA, which is indicated for the treatment of tumors of epithelial origin, such as colorectal carcinoma, lung adenocarcinoma, mucinous ovarian carcinoma, and endometrial adenocarcinoma; MORAb28, a human IgM monoclonal antibody binding to an antigen that is identified as a cell-surface antigen present on human melanomas and tumors of neuroectodermal origin; and MT110, a molecule that combines binding specificities for EpCAM and for CD3 on T cells. Micromet's product pipeline also consists of D93, a humanized, anti-metastatic, and anti-angiogenic monoclonal antibody for treatment of patients with solid tumors. It has strategic collaborations with MedImmune, Inc. for MT103; Nycomed for development of anti-GM-CSF antibodies; and Merck Serono Biopharmaceuticals S.A. for adecatumumab.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available